FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis

Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404. doi: 10.1007/s00259-004-1689-4. Epub 2004 Nov 12.

Abstract

Purpose: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is an imaging technique which enables detection of malignancies. FDG-PET has been established as a tool for the diagnosis of pancreatic carcinoma (CA). Early detection is mandatory as cure can only be achieved in non-advanced disease. This is, however, very difficult with conventional radiological techniques. Patients with chronic pancreatitis (CP) are at risk of developing CA. A simple, reliable screening method for malignant degeneration is highly desirable. We set out to investigate whether FDG-PET is able to detect CA in the setting of CP and can fulfil a potential role in the early detection of CA in CP.

Methods: FDG-PET was performed in 77 CP patients and in six patients with CP complicated by CA (CP + CA). We included 26 CA patients as a positive control. A positive scan was defined as focal FDG accumulation in the pancreas region.

Results: In 67 of the 77 CP (87%) patients, pancreatic FDG accumulation was absent. Six patients had significant accumulation. In CA, 24/26 patients had a positive PET. Five out of the six patients with CP + CA had focal uptake, while minor uptake was seen in one patient. FDG-PET was positive in almost all CA patients and CP + CA patients. FDG-PET was negative in the large majority (87%) of CP patients, which suggests that a positive PET scan in CP patients must lead to efforts to exclude a malignancy.

Conclusion: These data suggest that FDG-PET has a potential role as a diagnostic tool for detecting CA in longstanding CP.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Carcinoma / diagnostic imaging*
  • Carcinoma / etiology
  • Chronic Disease
  • Cohort Studies
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / etiology
  • Pancreatitis / complications
  • Pancreatitis / diagnostic imaging*
  • Prognosis
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18